Company intelligence / Profile preview

Joyo Bio

Guangzhou, China

Ownership: Private
Development stage: Other

Overview

Joyo Pharma is advancing JYP0322, a ROS1 inhibitor, into a pivotal phase 3 trial in China for second-line ROS fusion-positive NSCLC post prior ROS1-TKI, with phase 1 ORR of 55% reported at AACR[5]. Other programs include phase 3 in idiopathic pulmonary fibrosis and phase 2 in oncology[8].

Therapeutic areas: OncologyPulmonology
Modalities: Small molecule
Industry: Biotech

Partnerships

Erasca (ex-China rights to two preclinical RAS programs)

Beyond the preview

Go deeper on Joyo Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Joyo Bio.

Explore the full profile